Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Teresa Troiani et al.|The Lancet Oncology|2016Cited by 1k
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized TrialsEmmanuel Mitry, Philippe Rougier, Anthony Fields et al.|Journal of Clinical Oncology|2008Cited by 582
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialAndrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022Cited by 259
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|European Journal of Cancer|2023Cited by 14
242MO Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studiesFederica Miglietta, Valentina Guarneri, Maria Vittoria Dieci et al.|Annals of Oncology|2023Cited by 2